Literature DB >> 11520475

Treatment of the agitation of late-life psychosis and Alzheimer's disease.

C Salzman1.   

Abstract

In older as well as younger people, antipsychotic medication is commonly used to treat psychoses. In clinical practice, antipsychotic medication is also used to control severe behavioral disturbances such as agitation, wandering, self-mutilation, as well as assaultiveness. Neuroleptic and non-neuroleptic drug treatments are used to control severe agitation and disruptive behavior. Among typical neuroleptics, very low doses (e.g., 0.25 mg of haloperidol 1-4 times per day) may be effective and limit the development of severe extrapyramidal reactions. Recent experience suggests that the atypical neuroleptics, olanzaine, risperidone, and quetiapine, are also useful for controlling severe agitation in elderly demented nursing home residents. The benzamides are also known for the treatment of behavioral disturbances in Europe, but there is little experience in the U.S.A. Although research studies in this area are virtually nonexistent, growing clinical experience suggests that the following may be quite useful: 1) trazodone; 2) buspirone (Buspar); 3) anticonvulsants (e.g., valproate); and 4) beta-blockers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520475     DOI: 10.1016/s0924-9338(00)00525-3

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  7 in total

1.  Buspirone for anxiety and agitation in dementia.

Authors:  J P Cooper
Journal:  J Psychiatry Neurosci       Date:  2003-11       Impact factor: 6.186

Review 2.  Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status.

Authors:  Maria J Ramirez; Mitchell K P Lai; Rosa M Tordera; Paul T Francis
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

3.  Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease.

Authors:  Nikolai D Belyaev; Natalia N Nalivaeva; Natalia Z Makova; Anthony J Turner
Journal:  EMBO Rep       Date:  2008-12-05       Impact factor: 8.807

4.  Treatment advances in Alzheimer's disease based on the oxidative stress model.

Authors:  Avi L Friedlich; Raj K Rolston; Xiongwei Zhu; Michael W Marlatt; Rudy J Castellani; Akihiko Nunomura; Hyoung-Gon Lee; Gemma Casadesus; George Perry; Mark A Smith
Journal:  F1000 Med Rep       Date:  2009-07-08

Review 5.  Monoaminergic neuropathology in Alzheimer's disease.

Authors:  Goran Šimić; Mirjana Babić Leko; Selina Wray; Charles R Harrington; Ivana Delalle; Nataša Jovanov-Milošević; Danira Bažadona; Luc Buée; Rohan de Silva; Giuseppe Di Giovanni; Claude M Wischik; Patrick R Hof
Journal:  Prog Neurobiol       Date:  2016-04-12       Impact factor: 11.685

6.  Treatments for chronic psychosis.

Authors:  C A Tamminga; A C Lahti
Journal:  Dialogues Clin Neurosci       Date:  2001-12       Impact factor: 5.986

Review 7.  Medicinal Cannabis and Central Nervous System Disorders.

Authors:  Yuma T Ortiz; Lance R McMahon; Jenny L Wilkerson
Journal:  Front Pharmacol       Date:  2022-04-21       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.